XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis
复制标题
DOI：
10.3109/07357907.2015.1104689
复制
发表时间：
2016-02-07
影响因子：
2.4
通讯作者：
Ma, Li
中科院分区：
文献类型：
--
作者：
Guo, Yu;Xiong, Bing-Hong;Ma, Li
本Meta分析旨在评价XELOX(卡培他滨联合奥沙利铂)和FOLFOX(氟尿嘧啶联合奥沙利铂)治疗转移性结直肠癌的疗效和安全性。只纳入比较XELOX和FOLFOX的随机对照试验(RCT)。共有8个RCT的4363名患者可供分析。合并分析显示，两臂的OS、ORR差异无统计学意义。XELOX ARM组血小板减少、手足综合征和腹泻的发生率较高，而FOLFOX组中性粒细胞减少症的发生率较高。对于mCRC，XELOX的疗效与FOLFOX相似。
This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety.Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included.A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group.For mCRC, the effect of XELOX is similar to FOLFOX.